Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Regeneron Pharmaceuticals
Discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions

Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases.

It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP.

The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Number of employees : 6 200 people.
Sales per Businesses
20162017Delta
USD (in Million)%USD (in Million)%
Product3,33868.7%3,71863.3% +11.38%
Bayer Collaboration744.2715.3%938.0516% +26.04%
Sanofi Collaboration658.6713.6%877.1914.9% +33.18%
Other119.102.5%338.525.8% +184.23%
Sales per Regions
20162017Delta
USD (in Million)%USD (in Million)%
United States, European Union, Japan4,860100%5,872100% +20.82%
Managers
NameAgeSinceTitle
Leonard Schleifer651988Co-President, Chief Executive Officer & Director
George Damis Yancopoulos MD, PhD581989Co-President, Director & Chief Scientific Officer
P. Vagelos881995Chairman
Robert E. Landry542013Chief Financial Officer & Senior VP-Finance
Michael S. Brown, MD761991Independent Director
Joseph L. Goldstein, MD771991Independent Director
George L. Sing, MBA681988Independent Director
Arthur Frederick Ryan752003Independent Director
Christine A. Poon, MBA652010Independent Director
Marc Tessier-Lavigne, PhD582011Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 110,313,231 78,026,984 70.7% 3,990,021 3.6% 69.5%
Share B 10 1,911,354 0 0.0% 0 0.0%
Shareholders
NameEquities%
Sanofi 23,654,384 22.3%
Capital Research & Management Co. (World Investors) 6,062,272 5.71%
The Vanguard Group, Inc. 5,557,750 5.24%
BlackRock Fund Advisors 4,455,405 4.20%
Wellington Management Co. LLP 4,378,479 4.13%
Fidelity Management & Research Co. 4,146,443 3.91%
Loomis, Sayles & Co. LP 3,305,142 3.11%
SSgA Funds Management, Inc. 3,233,221 3.05%
Harris Associates LP 3,148,677 2.97%
Sands Capital Management LLC 2,305,811 2.17%
Holdings
NameEquities%Valuation
Intellia Therapeutics Inc (NTLA) 2,777,7776.43%79,499,978 USD
Markets and indexes
- Nasdaq Stock Market
- Nasdaq Global Select Market
- Nasdaq 100 / SP 500
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  REGN.O
- Datastream Code :  
Company contact information
Regeneron Pharmaceuticals
777 Road Old Saw Mill River
NY 10591 Tarrytown, New York
États-Unis (les)

Phone : +1 (914) 847 7000
Fax : +1
Internet : http://www.regeneron.com
Sector Bio Therapeutic Drugs
Connections : Regeneron Pharmaceuticals
National Math & Science Initiative, Inc.
Trustees of The University of Pennsylvania
Citizens Bank, NA (Providence, Rhode Island)
Lancet Capital Partners LLC
University of Pennsylvania
Regeneron Research Laboratories
Cold Spring Harbor Laboratory, Inc.
The International Biomedical Research Alliance
The Rockefeller Archive Center
American Philosophical Society
American Academy of Arts & Sciences
Bay Area Council Economic Institute
The Donald Danforth Plant Science Center
The Cooper Institute
National Academy of Medicine of United States
National Association of Corporate Directors
Manufacturing Services, Inc. (Washington)
Citizens Bank of Pennsylvania
The University of Texas Southwestern Medical Center
New Jersey Performing Arts Center
Crane Group Co.
The Prudential Insurance Company of America, Inc.
Stanford University
The American Association of Arts & Sciences
The Rockefeller University
Federal Reserve Bank of New York
Howard Hughes Medical Institute, Inc.
Stanford Alumni Association
Official Publications
© 2018 People , Fundamentals and Ownership
© 2018 Cofisem
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 26
Average target price 410 $
Spread / Average Target 20%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-10.29%36 325
GILEAD SCIENCES-1.52%90 269
VERTEX PHARMACEUTICALS9.82%42 594
GENMAB-12.11%8 451
NEUROCRINE BIOSCIENCES, INC.11.01%8 316
SAREPTA THERAPEUTICS INC113.80%7 949